Betta Pharmaceuticals Co., Ltd. (SHE:300558)
China
· Delayed Price · Currency is CNY 49.52
+0.04 (0.08%)
Apr 28, 2026, 3:04 PM CST
Betta Pharmaceuticals Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 | 2021 - 2017 |
| Operating Revenue | 3,700 | 3,578 | 2,827 | 2,417 | 2,342 | 2,206 | Upgrade
|
| Other Revenue | 31.67 | 31.67 | 64.95 | 39.41 | 34.18 | 40.05 | Upgrade
|
| Revenue | 3,732 | 3,609 | 2,892 | 2,456 | 2,377 | 2,246 | Upgrade
|
| Revenue Growth (YoY) | 21.40% | 24.81% | 17.74% | 3.35% | 5.82% | 20.08% | Upgrade
|
| Cost of Revenue | 784.36 | 738.66 | 538.52 | 404.48 | 268.69 | 174.44 | Upgrade
|
| Gross Profit | 2,947 | 2,871 | 2,353 | 2,052 | 2,108 | 2,071 | Upgrade
|
| Selling, General & Admin | 1,788 | 1,779 | 1,363 | 1,116 | 1,234 | 1,141 | Upgrade
|
| Research & Development | 495.01 | 510.87 | 501.9 | 640.14 | 699.9 | 565.95 | Upgrade
|
| Other Operating Expenses | 50.87 | 40.88 | 18.19 | 10.62 | -34.51 | 15.24 | Upgrade
|
| Operating Expenses | 2,334 | 2,330 | 1,876 | 1,772 | 1,901 | 1,723 | Upgrade
|
| Operating Income | 613.18 | 540.45 | 476.96 | 279.88 | 206.96 | 348.77 | Upgrade
|
| Interest Expense | -72.47 | -76.14 | -45.49 | -54.95 | -195.8 | -15.78 | Upgrade
|
| Interest & Investment Income | 3.25 | 4.29 | 6.78 | 10.23 | 10.88 | 33.35 | Upgrade
|
| Currency Exchange Gain (Loss) | -12.62 | -12.62 | 4.14 | 6.72 | 9.55 | -3.63 | Upgrade
|
| Other Non Operating Income (Expenses) | -10.79 | -1.19 | -6.57 | -4.96 | -9 | -0.84 | Upgrade
|
| EBT Excluding Unusual Items | 520.56 | 454.79 | 435.82 | 236.92 | 22.59 | 361.88 | Upgrade
|
| Gain (Loss) on Sale of Investments | 14.71 | -79.33 | -40.97 | -13.67 | -20.62 | 1.01 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.31 | 0.38 | -0.59 | -0.01 | 88.61 | 0.07 | Upgrade
|
| Asset Writedown | -0.01 | -0.01 | -28.05 | -1.07 | -3.01 | -0.03 | Upgrade
|
| Other Unusual Items | 38.1 | 38.53 | 27.95 | 99.9 | - | 27.01 | Upgrade
|
| Pretax Income | 573.68 | 414.36 | 394.16 | 322.07 | 87.57 | 389.93 | Upgrade
|
| Income Tax Expense | 151.77 | 128.15 | 7.18 | -11.54 | -37.19 | 10.37 | Upgrade
|
| Earnings From Continuing Operations | 421.9 | 286.21 | 386.98 | 333.62 | 124.76 | 379.56 | Upgrade
|
| Minority Interest in Earnings | 19.25 | 19.12 | 15.59 | 14.42 | 20.66 | 3.51 | Upgrade
|
| Net Income | 441.16 | 305.33 | 402.57 | 348.03 | 145.42 | 383.07 | Upgrade
|
| Net Income to Common | 441.16 | 305.33 | 402.57 | 348.03 | 145.42 | 383.07 | Upgrade
|
| Net Income Growth | 9.06% | -24.15% | 15.67% | 139.33% | -62.04% | -36.83% | Upgrade
|
| Shares Outstanding (Basic) | 419 | 418 | 419 | 419 | 416 | 416 | Upgrade
|
| Shares Outstanding (Diluted) | 419 | 418 | 419 | 419 | 416 | 416 | Upgrade
|
| Shares Change (YoY) | 0.57% | -0.26% | 0.01% | 0.72% | -0.02% | 2.32% | Upgrade
|
| EPS (Basic) | 1.05 | 0.73 | 0.96 | 0.83 | 0.35 | 0.92 | Upgrade
|
| EPS (Diluted) | 1.05 | 0.73 | 0.96 | 0.83 | 0.35 | 0.92 | Upgrade
|
| EPS Growth | 8.43% | -23.96% | 15.66% | 137.47% | -62.01% | -38.26% | Upgrade
|
| Free Cash Flow | 101.57 | 294.58 | 83.58 | -181.79 | -703.8 | -231.75 | Upgrade
|
| Free Cash Flow Per Share | 0.24 | 0.70 | 0.20 | -0.43 | -1.69 | -0.56 | Upgrade
|
| Dividend Per Share | 0.150 | 0.150 | 0.200 | 0.170 | 0.070 | 0.250 | Upgrade
|
| Dividend Growth | -25.00% | -25.00% | 17.65% | 142.86% | -72.00% | -19.36% | Upgrade
|
| Gross Margin | 78.98% | 79.53% | 81.38% | 83.53% | 88.69% | 92.23% | Upgrade
|
| Operating Margin | 16.43% | 14.97% | 16.49% | 11.39% | 8.71% | 15.53% | Upgrade
|
| Profit Margin | 11.82% | 8.46% | 13.92% | 14.17% | 6.12% | 17.06% | Upgrade
|
| Free Cash Flow Margin | 2.72% | 8.16% | 2.89% | -7.40% | -29.61% | -10.32% | Upgrade
|
| EBITDA | 1,206 | 1,088 | 845.1 | 578.14 | 453.58 | 517.89 | Upgrade
|
| EBITDA Margin | 32.32% | 30.15% | 29.22% | 23.54% | 19.09% | 23.06% | Upgrade
|
| D&A For EBITDA | 592.88 | 547.93 | 368.14 | 298.26 | 246.62 | 169.12 | Upgrade
|
| EBIT | 613.18 | 540.45 | 476.96 | 279.88 | 206.96 | 348.77 | Upgrade
|
| EBIT Margin | 16.43% | 14.97% | 16.49% | 11.39% | 8.71% | 15.53% | Upgrade
|
| Effective Tax Rate | 26.46% | 30.93% | 1.82% | - | - | 2.66% | Upgrade
|
| Revenue as Reported | 3,732 | 3,609 | 2,892 | 2,456 | 2,377 | 2,246 | Upgrade
|
| Advertising Expenses | - | - | - | - | 414.75 | 459.29 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.